1997
- -------------------------------------------------------------
Prutech Research and Annual
Development Partnership III Report
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
LETTER TO UNITHOLDERS FOR THE YEAR ENDED DECEMBER 31, 1997
1
PRUTECH III INVESTMENTS
The following investments and/or royalty rights had value at the end of the
year. The Partnership's position in each investment is as of December 31, 1997.
CREATIVE BIOMOLECULES, INC. (CBMI)
Position: 24,484 shares of common stock; royalty rights on soft tissue growth
factor products which expire December 1999
During the first quarter of 1997, the Partnership sold 441,898 shares of CBMI
common stock for approximately $5,019,000 and the Partnership exercised its
option to purchase 6,900 shares of CBMI common stock at an exercise price of
$8.50 per share for a total cost of $59,000. During the remainder of 1997, the
Partnership sold 49,900 shares of Creative BioMolecules, Inc. common stock for
approximately $506,000. The stock price of CBMI was $10.38 per share as of March
20, 1998.
It appears unlikely that the Partnership's projects will produce sales
royalties for the Partnership as the Partnership's royalty rights expire in
1999.
FOREST LABORATORIES, INC. (FRX)
Position: Royalty rights to a treatment of Alzheimer's disease which expire
December 1999
Clinical studies on Synapton, a drug developed by FRX for the treatment of
Alzheimer's disease, were completed during 1996. The filing of a New Drug
Application with the Food and Drug Administration, seeking approval of Synapton,
was made on November 18, 1997.
KOPIN CORPORATION (KOPN)
Position: 13,310 shares of common stock
During 1997, the Partnership sold 524,023 shares of Kopin Corporation common
stock for approximately $7,852,000. The stock price of Kopin Corporation was
$17.19 per share as of March 20, 1998.
SOMATIX THERAPY CORPORATION (SOMA)/CELL GENESYS CORPORATION (CEGE)
Position: 17,465 shares of CEGE common stock
During the first quarter of 1997, the Partnership sold 205,000 shares of SOMA
common stock for approximately $517,000. At March 31, 1997, the General Partner
concluded that an impairment in value that was not temporary had occurred for
the Partnership's equity investment in SOMA. As a result, the value of the
Partnership's 295,000 shares of common stock was written down by $295,000.
During the second quarter of 1997, the Partnership sold 6,000 shares of SOMA
common stock for approximately $12,000.
On June 2, 1997, Cell Genesys Corporation acquired Somatix Therapy
Corporation. As a result, the Partnership received 111,265 shares of CEGE common
stock or 0.385 shares for each of its 289,000 shares of SOMA common stock.
During the second half of 1997, the Partnership sold 93,800 shares of CEGE
common stock for approximately $661,000. The stock price of CEGE was $6.25 per
share as of March 20, 1998.
2
1177 Avenue of the Americas Telephone 212 596 7000
New York, NY 10036 Fascimile 212 596 8910
Price Waterhouse LLP (LOGO)
REPORT OF INDEPENDENT ACCOUNTANTS
February 12, 1998
To the Partners of
PruTech Research and Development Partnership III
In our opinion, the accompanying statements of financial condition and the
related statements of operations, changes in partners' capital and cash flows
present fairly, in all material respects, the financial position of PruTech
Research and Development Partnership III at December 31, 1997 and 1996, and the
results of its operations and the changes in its cash flows for the years then
ended in conformity with generally accepted accounting principles. These
financial statements are the responsibility of the general partner; our
responsibility is to express an opinion on these financial statements based on
our audits. We conducted our audits of these statements in accordance with
generally accepted auditing standards which require that we plan and perform the
audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement. An audit includes examining, on a test basis,
evidence supporting the amounts and disclosures in the financial statements,
assessing the accounting principles used and significant estimates made by the
general partner, and evaluating the overall financial statement presentation. We
believe that our audits provide a reasonable basis for the opinion expressed
above.
/s/ Price Waterhouse LLP
3
Deloitte &
Touche LLP
(LOGO)
- ------------------------------------------------------------------------------
Two World Financial Center Telephone: (212) 436-2000
New York, New York 10281-1414 Facsimile: (212) 436-5000
INDEPENDENT AUDITORS' REPORT
To the Partners of
PruTech Research and Development Partnership III
We have audited the accompanying statements of operations, changes in partners'
capital and cash flows of PruTech Research and Development Partnership III (a
California limited partnership) for the year ended December 31, 1995. These
financial statements are the responsibility of the General Partner. Our
responsibility is to express an opinion on these financial statements based on
our audit.
We conducted our audit in accordance with generally accepted auditing standards.
Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material
misstatements. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by the
General Partner, as well as evaluating the overall financial statement
presentation. We believe that our audit provides a reasonable basis for our
opinion.
In our opinion, such financial statements present fairly, in all material
respects, the results of operations and cash flows of PruTech Research and
Development Partnership III for the year ended December 31, 1995 in conformity
with generally accepted accounting principles.
/s/ Deloitte & Touche LLP
February 13, 1996
3A
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF FINANCIAL CONDITION
December 31,
-----------------------------
1997 1996
- ----------------------------------------------------------------------------------------------------
ASSETS
Cash and cash equivalents $3,668,595 $ 2,342,441
Investments in equity securities 552,790 13,321,925
------------ ------------
Total assets $4,221,385 $15,664,366
------------ ------------
------------ ------------
LIABILITIES AND PARTNERS' CAPITAL
Liabilities
Accrued expenses and other liabilities $ 84,357 $ 80,438
Accrued management fee 62,500 204,670
------------ ------------
Total liabilities 146,857 285,108
------------ ------------
Contingencies
Partners' capital
Unitholders (40,934 units issued and outstanding) 3,405,966 8,312,200
General partner 386,179 931,316
Unrealized gain on investments in equity securities 282,383 6,135,742
------------ ------------
Total partners' capital 4,074,528 15,379,258
------------ ------------
Total liabilities and partners' capital $4,221,385 $15,664,366
------------ ------------
------------ ------------
- ----------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of these statements.
4
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF OPERATIONS
Year ended December 31,
-----------------------------------------
1997 1996 1995
- ----------------------------------------------------------------------------------------------------
REVENUES
Gain on sale of investments in equity securities $7,888,065 $5,194,202 $ 8,998,197
Interest and other income 135,893 38,019 71,671
Royalty income -- 216,665 --
Termination of royalty rights -- -- 2,241,783
---------- ---------- -----------
8,023,958 5,448,886 11,311,651
---------- ---------- -----------
EXPENSES
Management fee 534,340 818,680 818,680
Write-down of investments in equity securities 295,000 -- --
General and administrative 138,378 95,688 166,060
Interest -- -- 18,070
---------- ---------- -----------
967,718 914,368 1,002,810
---------- ---------- -----------
Net income $7,056,240 $4,534,518 $10,308,841
---------- ---------- -----------
---------- ---------- -----------
ALLOCATION OF NET INCOME
Unitholders $6,350,616 $4,081,066 $ 9,277,957
---------- ---------- -----------
---------- ---------- -----------
General partner $ 705,624 $ 453,452 $ 1,030,884
---------- ---------- -----------
---------- ---------- -----------
Net income per unit $ 155.14 $ 99.70 $ 226.66
---------- ---------- -----------
---------- ---------- -----------
- ----------------------------------------------------------------------------------------------------
STATEMENTS OF CHANGES IN PARTNERS' CAPITAL
UNREALIZED
GENERAL GAIN ON
UNITHOLDERS PARTNER INVESTMENTS TOTAL
- ------------------------------------------------------------------------------------------------------
Partners' capital--December 31, 1994 $ 5,350,413 $ 602,229 $10,750,699 $ 16,703,341
Net income 9,277,957 1,030,884 -- 10,308,841
Distributions (7,122,516) (791,391) -- (7,913,907)
Change in unrealized gain on
investments in equity securities -- -- 503,804 503,804
------------ ----------- ----------- ------------
Partners' capital--December 31, 1995 7,505,854 841,722 11,254,503 19,602,079
Net income 4,081,066 453,452 -- 4,534,518
Distributions (3,274,720) (363,858) -- (3,638,578)
Change in unrealized gain on
investments in equity securities -- -- (5,118,761 ) (5,118,761)
------------ ----------- ----------- ------------
Partners' capital--December 31, 1996 8,312,200 931,316 6,135,742 15,379,258
Net income 6,350,616 705,624 -- 7,056,240
Distributions (11,256,850) (1,250,761) (12,507,611)
Change in unrealized gain on
investments in equity securities -- -- (5,853,359 ) (5,853,359)
------------ ----------- ----------- ------------
Partners' capital--December 31, 1997 $ 3,405,966 $ 386,179 $ 282,383 $ 4,074,528
------------ ----------- ----------- ------------
------------ ----------- ----------- ------------
- ------------------------------------------------------------------------------------------------------
The accompanying notes are an integral part of these statements.
5
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF CASH FLOWS
Year ended December 31,
---------------------------------------------
1997 1996 1995
- -----------------------------------------------------------------------------------------------------
CASH FLOWS FROM OPERATING ACTIVITIES
Interest and other income received $ 135,893 $ 38,019 $ 71,671
Management fee paid (676,510) (818,680) (1,637,360)
General and administrative expenses paid (134,459) (88,341) (154,963)
Royalty income received -- 216,665 389,023
Cash received for other assets -- 216,669 --
Interest paid -- -- (55,742)
------------ ----------- ------------
Net cash used in operating activities (675,076) (435,668) (1,387,371)
------------ ----------- ------------
CASH FLOWS FROM INVESTING ACTIVITIES
Proceeds from the sale of investments in equity
securities 14,567,491 5,935,995 9,010,326
Purchase of investments in equity securities (58,650) -- --
Proceeds from the termination of royalty rights -- -- 2,241,783
------------ ----------- ------------
Net cash provided by investing activities 14,508,841 5,935,995 11,252,109
------------ ----------- ------------
CASH FLOWS FROM FINANCING ACTIVITIES
Distributions (12,507,611) (3,638,578) (7,913,907)
Repayment of note payable -- -- (1,622,223)
------------ ----------- ------------
Net cash used in financing activities (12,507,611) (3,638,578) (9,536,130)
------------ ----------- ------------
Net increase in cash and cash equivalents 1,326,154 1,861,749 328,608
Cash and cash equivalents at beginning of year 2,342,441 480,692 152,084
------------ ----------- ------------
Cash and cash equivalents at end of year $ 3,668,595 $ 2,342,441 $ 480,692
------------ ----------- ------------
------------ ----------- ------------
- -----------------------------------------------------------------------------------------------------
(continued on next page)
6
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
STATEMENTS OF CASH FLOWS (Cont'd)
Year ended December 31,
---------------------------------------------
1997 1996 1995
- -----------------------------------------------------------------------------------------------------
RECONCILIATION OF NET INCOME TO NET CASH USED IN
OPERATING ACTIVITIES
Net income $ 7,056,240 $ 4,534,518 $ 10,308,841
------------ ----------- ------------
Adjustments to reconcile net income to net cash used
in operating activities:
Gain on sale of investments in equity securities (7,888,065) (5,194,202) (8,998,197)
Write-down of investments in equity securities 295,000 -- --
Termination of royalty rights -- -- (2,241,783)
Changes in:
Royalties receivable -- -- 389,023
Accrued management fee (142,170) -- (818,680)
Accrued expenses and other liabilities 3,919 7,347 (26,575)
Other assets -- 216,669 --
------------ ----------- ------------
Total adjustments (7,731,316) (4,970,186) (11,696,212)
------------ ----------- ------------
Net cash used in operating activities $ (675,076) $ (435,668) $ (1,387,371)
------------ ----------- ------------
------------ ----------- ------------
- -----------------------------------------------------------------------------------------------------
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING ACTIVITIES
1997
At March 31, 1997, the General Partner concluded that an impairment in value
that was not temporary had occurred for the Partnership's equity investment in
Somatix Therapy Corporation. As a result, the value of the Partnership's
295,000 shares of common stock was written down by $295,000.
On June 2, 1997, Cell Genesys Corporation acquired Somatix Therapy Corporation.
As a result, the Partnership received 111,265 of Cell Genesys Corporation
common stock or 0.385 shares for each of its 289,000 shares of Somatix Therapy
Corporation common stock.
1995
Exercised a warrant to acquire, on a net issuance basis, 171,635 shares of
Interleaf, Inc. common stock.
- -------------------------------------------------------------------------------
The accompanying notes are an integral part of these statements.
7
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
NOTES TO FINANCIAL STATEMENTS
A. General
PruTech Research and Development Partnership III (the 'Partnership'), a
California limited partnership, was formed on June 2, 1986 and will terminate on
December 31, 2006 unless terminated sooner under the provisions of the Agreement
of Limited Partnership, as amended (the 'Partnership Agreement'). Capital
resources were originally provided by the sale of depositary units and by
contributions of the General Partner equal to ten percent of depositary
contributions. The Partnership was formed to seek cash flow from the research
and development of new technologies with potential commercial applications. The
general partner of the Partnership is R&D Funding Corp (the 'General Partner'),
an affiliate of Prudential Securities Incorporated ('PSI'). Both the General
Partner and PSI are wholly owned subsidiaries of Prudential Securities Group
Inc. ('PSGI'). The assignor limited partner is Prudential-Bache Investor
Services Inc., an affiliate of the General Partner, who has assigned
substantially all the rights attributable to its limited partnership interest to
investors. At December 31, 1997, the Partnership held equity investments or
active royalty rights relating to four portfolio companies.
B. Summary of Significant Accounting Policies
Basis of accounting
The books and records of the Partnership are maintained on the accrual basis
of accounting in accordance with generally accepted accounting principles.
The preparation of financial statements in conformity with generally accepted
accounting principles requires the General Partner to make estimates and
assumptions that affect the reported amounts of assets and liabilities and the
disclosure of contingent assets and liabilities at the date of the financial
statements as well as the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Certain balances from prior years have been reclassified to conform with the
current financial statement presentation.
Cash and cash equivalents
Cash and cash equivalents include money market funds.
Investments
The Partnership's equity securities that have readily determinable fair
values are classified as available-for-sale securities. These securities are
measured at fair value in the statements of financial condition and unrealized
gains and losses are reported as a separate component of partners' capital.
Equity securities traded on a national securities exchange or the Nasdaq
national market are valued at the last reported sales price on the primary
exchange on which they are traded. Equity securities traded in the
over-the-counter market and thinly traded securities are valued at the mean
between the last reported bid and asked prices. Equity securities which are not
readily marketable are accounted for under the cost method.
The carrying value of an investment is written down to its fair value when a
decline in value is considered to be other than temporary. The Partnership uses
the average cost method to determine gains or losses on the sale of securities.
Royalty income
Royalty income represents revenue generated from licenses granted by the
Partnership.
8
Management fee
This fee provides for the cost of overseeing, supervising and monitoring the
conduct of the development projects and for overseeing and monitoring product
exploitation resulting from the development projects.
The General Partner was paid an annual management fee equal to two percent of
the unitholders' original capital contributions through June 30, 1997. Effective
July 1, 1997, the General Partner reduced its management fee to the greater of
(a) $250,000 annually or (b) ten percent of the aggregate amount received from
the Partnership's royalty position in a treatment for Alzheimer's disease with
Forest Laboratories, Inc. after July 1, 1997 until the dissolution and
liquidation of the Partnership, not to exceed the aggregate management fee
payable under the terms of the Partnership Agreement ($818,680 per annum).
Income taxes
The Partnership is not required to provide for, or pay, any Federal or state
income taxes. Income tax attributes that arise from its operations are passed
directly to the individual partners. The Partnership may be subject to other
state and local taxes in jurisdictions in which it operates.
Profit and loss allocations and distributions
Profits and losses are allocated ninety percent to the unitholders and ten
percent to the General Partner until such time as the total net profits
allocated to each unitholder equal all losses previously allocated whereupon the
General Partner will be allocated net profits in an additional amount of
twenty-five percent with a corresponding reduction to the unitholders to be
shared in proportion to their capital contributions.
Distributions of cash are made in accordance with the Partnership Agreement
and are allocated ninety percent to the unitholders and ten percent to the
General Partner.
C. Royalties
At December 31, 1997 and 1996, the Partnership retains certain royalty rights
with Forest Laboratories, Inc. and Creative BioMolecules, Inc. whose carrying
values for financial reporting purposes are zero. The royalty rights with Forest
Laboratories, Inc. ('Forest') relate to Synapton, a drug developed by Forest for
the treatment of Alzheimer's disease. Forest filed a new drug application with
the Food and Drug Administration, seeking approval of Synapton, on November 18,
1997. The Partnership's royalty rights with Forest and Creative BioMolecules,
Inc. will expire in December 1999.
On April 1, 1990, the Partnership entered into a Technology Development
Investment Agreement with Kopin Corporation ('Kopin') for the development of LED
technology. Pursuant to the Agreement, Kopin was obligated to pay to the
Partnership royalties on the sale of products containing the technology through
April 1, 1996, with a minimum royalty payment of $433,334 due April 1, 1996
(payable in cash or by the delivery of a promissory note). Kopin agreed to pay
cash for the minimum royalty because the Partnership also agreed to transfer to
Kopin its Gas technology developed under an earlier contract. During the second
quarter of 1996, the Partnership received the $433,334 minimum royalty payment
of which $216,669 represented a reduction of its receivable from Kopin and
$216,665 was recorded as royalty income. As a result, the Partnership holds no
technology or royalty positions with Kopin and, therefore, no further royalties
will be received by the Partnership from Kopin.
In November 1995, the Partnership and Interleaf, Inc. ('Interleaf') agreed to
settle all royalty and other disputes between them and the Partnership sold to
Interleaf the Partnerships' right, title and interest in technology licensed to
Interleaf for $2,100,000. In connection with this transaction, the Partnership
applied $375,081 of the proceeds to its outstanding royalty receivable balance
and the remaining $1,724,919 was recognized as income. During 1995, revenues
from Interleaf inclusive of the gain on common stock sold (see Note D)
represented approximately thirty-two percent of the Partnership's total 1995
revenues.
In March 1995, the Partnership and the MacNeal-Schwendler Corporation ('MNS')
agreed to terminate the Partnership's contractual rights with respect to MNS
software and to transfer the technology relating to the software to MNS in
exchange for $516,870. No further royalty payments will be received by the
Partnership from MNS as a result of this agreement.
9
D. Investments
In connection with certain of its research and development contracts, the
Partnership has exercised its warrants or has converted its technology, royalty
rights, warrants or notes receivable into an equity position in the companies
performing the research and development.
Investments in equity securities available-for-sale at December 31, 1997 and
1996 include the following:
1997 1996
-------------------------------------------------- --------------------------------------------------
Gross unrealized Carrying Gross unrealized Carrying
Shares Cost basis gains value Shares Cost basis gains value
- ------------------------------------------------------------------------ --------------------------------------------
Creative BioMolecules,
Inc.-Common Stock 24,484 $ 80,124 $100,446 $ 180,570 509,382 $1,666,928 $3,617,910 $ 5,284,838
Kopin Corporation-
Common Stock 13,310 99,556 124,212 223,768 537,333 4,019,255 2,361,582 6,380,837
Cell Genesys
Corporation-
Common Stock 17,465 90,727 57,725 148,452 -- -- -- --
Somatix Therapy
Corporation-Common
Stock -- -- -- -- 500,000 1,500,000 156,250 1,656,250
---------- ---------------- ----------- ---------- ---------------- -----------
$270,407 $282,383 $ 552,790 $7,186,183 $6,135,742 $13,321,925
---------- ---------------- ----------- ---------- ---------------- -----------
---------- ---------------- ----------- ---------- ---------------- -----------
The gross unrealized gains would be allocated ninety percent to the
unitholders and ten percent to the General Partner if realized at December 31,
1997; however, there is no assurance that the Partnership would receive these
amounts in the event of the sale of its position in these securities.
Creative BioMolecules, Inc.
During the first quarter of 1997, the Partnership sold 441,898 shares of
Creative BioMolecules, Inc. common stock with a cost basis of approximately
$1,446,000 resulting in a gain of approximately $3,573,000, and the Partnership
exercised its option to purchase 6,900 shares of Creative BioMolecules, Inc.
common stock at an exercise price of $8.50 per share for a total cost of
approximately $59,000. During the remainder of 1997, the Partnership sold 49,900
shares of Creative BioMolecules, Inc. common stock with a cost basis of
approximately $199,000 resulting in a gain of approximately $307,000. During
1997, revenues from the Partnership's investment in Creative BioMolecules, Inc.
represented approximately 48% of the Partnership's total 1997 revenues.
During December 1996, the Partnership sold 214,900 shares of Creative
BioMolecules, Inc. common stock with a cost basis of approximately $703,000
resulting in a gain of approximately $1,573,000. During 1996, revenues from the
Partnership's investment in Creative BioMolecules, Inc. represented
approximately 29% of the Partnership's total 1996 revenues.
Kopin Corporation
During 1997, the Partnership sold 524,023 shares of Kopin Corporation common
stock with a cost basis of approximately $3,920,000 resulting in a gain of
approximately $3,932,000. During 1997, revenues from the Partnership's
investment in Kopin Corporation represented approximately 49% of the
Partnership's total 1997 revenues.
During the first quarter of 1996, the Partnership sold 4,334 shares of Kopin
Corporation common stock with a cost basis of approximately $32,000 resulting in
a gain of approximately $27,000.
Somatix Therapy Corporation/Cell Genesys Corporation
During the first quarter of 1997, the Partnership sold 205,000 shares of
Somatix Therapy Corporation common stock with a cost basis of approximately
$615,000 resulting in a loss of approximately $98,000. At March 31, 1997, the
General Partner concluded that an impairment in value that was not temporary had
occurred for the Partnership's equity investment in Somatix Therapy Corporation.
As a result, the value of the Partnership's common stock was written down by
$295,000. During the second quarter of 1997, the Partnership sold 6,000 shares
of Somatix Therapy Corporation common stock with a cost basis of approximately
$12,000 resulting in no gain or loss to the Partnership.
10
On June 2, 1997, Cell Genesys Corporation acquired Somatix Therapy
Corporation. As a result, the Partnership received 111,265 shares of Cell
Genesys Corporation common stock or 0.385 shares for each of its 289,000 shares
of Somatix Therapy Corporation common stock.
During the second half of 1997, the Partnership sold 93,800 shares of Cell
Genesys Corporation common stock with a cost basis of approximately $487,000
resulting in a gain of approximately $174,000.
Forest Laboratories, Inc.
During the first quarter of 1996, the Partnership sold its remaining 75,000
shares of Forest Laboratories, Inc. common stock with a cost basis of
approximately $6,000 resulting in a gain of approximately $3,594,000. During
1996, revenues relating to the Partnership's investment in Forest Laboratories,
Inc. represented approximately sixty-six percent of the Partnership's total 1996
revenues.
During 1995, the Partnership sold 148,410 shares of Forest Laboratories, Inc.
common stock with a cost basis of approximately $12,000 resulting in a gain of
approximately $7,121,000. During 1995, revenues relating to the Partnership's
investment in Forest Laboratories, Inc. represented approximately sixty-three
percent of the Partnership's total revenues.
Interleaf, Inc.
In 1995, the Partnership exercised a warrant to acquire, on a net issuance
basis, 171,635 shares of Interleaf, Inc. common stock which the Partnership sold
for approximately $1,878,000.
E. Income Taxes
The following is a reconciliation of net income for financial reporting
purposes to net income for tax reporting purposes:
Year ended December 31,
------------------------------------------
1997 1996 1995
------------------------------------------
Net income per financial statements $ 7,056,240 $4,534,518 $10,308,841
Gain on sale of investments in equity
securities (1,107,903) -- --
Write-down/write-off of investment in equity
securities 295,000 (511,194) (66,668)
Royalty income -- (76,698) --
Expiration of stock warrants -- -- (180,000)
----------- ---------- -----------
Tax basis net income $ 6,243,337 $3,946,626 $10,062,173
----------- ---------- -----------
----------- ---------- -----------
The differences between the tax basis and book basis of partners' capital are
primarily attributable to the cumulative effect of the book to tax income
adjustments.
F. Related Parties
The General Partner and its affiliates perform certain services for the
Partnership (for which they are reimbursed through the management fee) which
include, but are not limited to: accounting and financial management; registrar,
transfer and assignment functions; asset management; investor communications and
other administrative services. The Partnership also reimburses an affiliate of
the General Partner for printing services. The costs and expenses were:
Year ended December 31,
----------------------------------
1997 1996 1995
----------------------------------
Management fee $534,340 $818,680 $818,680
Printing 13,448 11,849 18,691
-------- -------- --------
$547,788 $830,529 $837,371
-------- -------- --------
-------- -------- --------
Effective July 1, 1997, the General Partner reduced its management fee to the
greater of (a) $250,000 annually or (b) ten percent of the aggregate amount
received from the Partnership's royalty position in a treatment for Alzheimer's
disease with Forest Laboratories, Inc. after July 1, 1997 until the dissolution
and liquidation of the Partnership, not to exceed the aggregate management fee
payable under the terms of the Partnership Agreement ($818,680 per annum).
11
Printing costs payable to an affiliate of the General Partner (which are
included in accrued expenses) as of December 31, 1997 and 1996 were $7,788 and
$4,943, respectively.
Prudential Securities Incorporated, an affiliate of R&D Funding Corp, owned
724 units in the Partnership at December 31, 1997.
The Partnership maintains an account with the Prudential Institutional
Liquidity Portfolio Fund, an affiliate of R&D Funding Corp, for investment of
its available cash in short-term instruments pursuant to the guidelines
established by the Partnership Agreement.
The Partnership has engaged in research and development co-investment
projects with PruTech Research and Development Partnership, PruTech Research and
Development Partnership II and PruTech Project Development Partnership
(collectively, the 'PruTech R&D Partnerships'), for which R&D Funding Corp
serves as the general partner. The allocation of the co-investment projects'
profits or losses among the PruTech R&D Partnerships is consistent with the
costs incurred to fund the research and development projects.
G. Contingencies
On April 15, 1994, a multiparty petition captioned Mack et al. v. Prudential
Securities Incorporated et al. (Cause No. 94-17695) was filed in the 80th
Judicial District Court of Harris County, Texas, purportedly on behalf of
investors in the Partnership against the Partnership, the General Partner, PSI,
The Prudential Insurance Company of America and a number of other defendants.
The petition alleges common law fraud and fraud in the inducement and negligent
misrepresentation in connection with the offering of the Partnership; negligence
and breach of fiduciary duty in connection with the operation of the
Partnership; civil conspiracy; and violations of the federal Securities Act of
1933 (sections 11 and 12), and of the Texas Securities and Deceptive Trade
Practices statutes. The suit seeks, among other things, compensatory and
punitive damages, costs and attorneys' fees.
The General Partner, PSI and the Partnership believe they have meritorious
defenses to the complaint and are vigorously defending themselves in this
action. The claims of most plaintiffs have been settled or dismissed. It is
currently expected that the remaining claims will be resolved shortly. The
Partnership has not contributed to any settlement or paid any costs of the
litigation, nor is it anticipated that it will.
12
PRUTECH RESEARCH AND DEVELOPMENT PARTNERSHIP III
(a limited partnership)
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
Liquidity and Capital Resources
As of December 31, 1997, the Partnership had approximately $3,669,000 of cash
and cash equivalents which is an increase of approximately $1,326,000 as
compared to December 31, 1996. The increase in cash and cash equivalents was
primarily due to the proceeds from the sales of certain investments in equity
securities, as further discussed below, reduced by the payment of distributions
and management fees.
As of December 31, 1997, the Partnership had approximately $270,000 invested
in equity securities with an aggregate market value which exceeded its cost.
Certain of these investments are in development stage companies which are more
speculative and higher in risk than other equity investments. Additionally, the
realization of this market value is further impacted by market volume capacity.
The amount to be distributed by the Partnership in future quarters will be based
on the extent to which the market value of its investments can be realized and
from the revenue stream from royalties and interest income. It is not expected
that the Partnership's eventual total distributions will equal the Unitholders'
initial investments. The Partnership's royalty positions with Forest
Laboratories, Inc. and Creative BioMolecules, Inc. did not generate royalty
income for the Partnership during the three years ended December 31, 1997.
During the first quarter of 1997, the Partnership sold 441,898 shares of
Creative BioMolecules, Inc. common stock for approximately $5,019,000, and the
Partnership exercised its option to purchase 6,900 shares of Creative
BioMolecules, Inc. common stock at an exercise price of $8.50 per share for a
total cost of approximately $59,000. Also, during the first quarter of 1997, the
Partnership sold 173,189 shares of Kopin Corporation common stock for
approximately $2,297,000, and 205,000 shares of Somatix Therapy Corporation
common stock for approximately $517,000.
In February and March of 1997, the Partnership made distributions of
$4,548,222 and $3,411,167, respectively. Unitholders received a total of
$4,093,400 ($100 per unit) and $3,070,050 ($75 per unit) and the General Partner
received the remainder.
During the second quarter of 1997, the Partnership sold 219,274 shares of
Kopin Corporation common stock for approximately $2,848,000, and 6,000 shares of
Somatix Therapy Corporation common stock for approximately $12,000.
On June 2, 1997, Cell Genesys Corporation acquired Somatix Therapy
Corporation. As a result, the Partnership received 111,265 shares of Cell
Genesys Corporation common stock or 0.385 shares for each of its 289,000 shares
of Somatix Therapy Corporation common stock.
During the third quarter of 1997, the Partnership sold 19,900 shares of
Creative BioMolecules, Inc. common stock for approximately $190,000, 99,754
shares of Kopin Corporation common stock for approximately $1,976,000, and
72,100 shares of Cell Genesys Corporation common stock for approximately
$460,000.
During August 1997, the Partnership made a $4,548,222 distribution, of which
$4,093,400 ($100 per unit) was paid to the Unitholders, and the remainder to the
General Partner.
During the fourth quarter of 1997, the Partnership sold 30,000, 31,806, and
21,700 shares of Creative BioMolecules, Inc. common stock, Kopin Corporation
common stock, and Cell Genesys Corporation common stock for approximately
$316,000, $729,000, and $201,000, respectively.
Results of Operations
Net income for the years ended December 31, 1997, 1996 and 1995 was
approximately $7,056,000, $4,535,000 and $10,309,000, respectively. The primary
reasons for the fluctuations in operating results are discussed below.
13
During 1997, the Partnership recorded gains on the sale of common stock
totalling approximately $7,888,000, including gains of $3,932,000 and $3,880,000
on the sale of common stock of Kopin Corporation and Creative BioMolecules,
Inc., respectively. During 1996, the Partnership recorded gains of approximately
$3,594,000 and $1,573,000 on the sale of 75,000 shares of Forest Laboratories,
Inc. common stock and 214,900 shares of Creative BioMolecules, Inc. common
stock, respectively. During 1995, the Partnership recorded gains of
approximately $7,121,000 and $1,878,000, respectively, on the sale of 148,410
shares of Forest Laboratories, Inc. common stock and 171,635 shares of
Interleaf, Inc. ('Interleaf') common stock.
At March 31, 1997, the General Partner concluded that an impairment in value
that was not temporary had occurred for the Partnership's equity investment in
Somatix Therapy Corporation. As a result, the value of the Partnership's common
stock was written down by $295,000.
In November 1995, the Partnership and Interleaf agreed to settle all royalty
and other disputes between them and to sell to Interleaf its right, title and
interest in technology licensed to Interleaf for $2,100,000. In connection with
this transaction, the Partnership applied $375,000 of the proceeds to its
outstanding royalty receivable balance and the remaining $1,725,000 was
recognized as income. In March 1995, the Partnership and the MacNeal-Schwendler
Corporation ('MNS') agreed to terminate the Partnership's contractual rights
with respect to MNS software and to transfer the technology relating to the
software to MNS in exchange for approximately $517,000. No further royalty
payments will be received by the Partnership from Interleaf or MNS as a result
of these agreements.
No royalties were earned by the Partnership in 1997 and 1995. Royalty income
for the year ended December 31, 1996 was approximately $217,000 and related to
an agreement in which the Partnership received a minimum royalty payment from
Kopin Corporation and transferred to Kopin Corporation its rights to certain
technologies and royalties. As a result of the agreement, the Partnership holds
no technology or royalty positions with Kopin Corporation.
Interest and other income for the year ended December 31, 1997 increased by
approximately $98,000 as compared to 1996 and decreased by approximately $34,000
for the year ended December 31, 1996 as compared to 1995. These fluctuations in
interest and other income largely reflect the level of Partnership funds
invested in short-term instruments which has varied with the timing of sales of
investments in equity securities and subsequent distributions to unitholders.
Management fees for the year ended 1997 decreased by approximately $284,000
from the 1996 and 1995 amounts. Effective July 1, 1997, the General Partner
reduced its management fee to the greater of (a) $250,000 annually or (b) ten
percent of the aggregate amount received from the Partnership's royalty position
in a treatment for Alzheimer's disease with Forest Laboratories, Inc. after July
1, 1997 until the dissolution and liquidation of the Partnership, not to exceed
the aggregate management fee payable under the terms of the Agreement of Limited
Partnership ($818,680 per annum.)
General and administrative expenses for the year ended December 31, 1997
increased by approximately $43,000 as compared to 1996 and decreased by
approximately $70,000 for the year ended December 31, 1996 as compared to 1995.
The 1997 increase was due primarily to professional and other costs incurred in
1997 in considering alternatives for the orderly liquidation of the Partnership.
The 1996 decrease as compared to 1995 primarily reflected lower evaluation and
monitoring expenses as overall activity decreased in the Partnership's R&D
projects and license agreements.
Inflation
Inflation has had no direct material impact on operations or on the financial
condition of the Partnership from inception through December 31, 1997.
14
OTHER INFORMATION
The Partnership's Annual Report on Form 10-K as filed with the Securities and
Exchange Commission is available to Unitholders without charge upon written
request to:
PruTech Research and Development Partnership III
P.O. Box 2016
Peck Slip Station
New York, New York 10272-2016
15
Peck Slip Station BULK RATE
P.O. Box 2016 U.S. POSTAGE
New York, NY 10272 PAID
Automatic Mail
PRUTEC386/170864